Pelthos Therapeutics Inc. (PTHS)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $28.10M
Last updated: Nov 17, 2026 at 4:10 PM ET
Pelthos Therapeutics Inc. (PTHS) Statistics
Pelthos Therapeutics (PTHS) has a market cap of $28.10M and an enterprise value of $75.67M. Revenue grew 592.92% over the last 12 months from the 12 months before. It kept -152.16% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 169.24% above the market cap, as debt exceeds cash.
| Market Cap | $28.10M |
|---|---|
| Enterprise Value | $75.67M |
| Latest price (Nov 17, 2026) | $6.89 |
Key Dates
The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 0.5x.
| P/S Ratio | 0.5x |
|---|---|
| Forward P/S | 0.5x |
Price Statistics
The stock is down 79.50% over 52 weeks and trades 60.54% below its 50-day average.
| Beta (1Y) | 1.01 |
|---|---|
| 52-Week Change | -79.50% |
| 1-Month Change | -65.99% |
| 3-Month Change | -73.32% |
| 6-Month Change | -74.48% |
| Total Return (1Y) | -79.50% |
| Return vs SPY (1Y) | -89.91% |
| Max Drawdown (1Y) | -79.31% |
| Max Drawdown (3Y) | -88.73% |
| Sharpe Ratio (1Y) | -1.57 |
| Correlation with SPY (1Y) | 0.14 |
| 50-Day Average | $17.46 |
| 200-Day Average | $23.26 |
| 52-Week Range | $7.12 to $31.65 |
| RSI (14 Days) | 24.0 |
| Average Volume (20 Days) | 67.62K |
Financial Position
Current assets cover 1.78x current liabilities.
| Current Ratio | 1.78x |
|---|---|
| Quick Ratio | 1.10x |
| Interest Coverage | -7.37x |
Returns and Efficiency
Return on invested capital is -95.44% over the last 12 months.
| Return on Assets (ROA) | -60.59% |
|---|---|
| Return on Invested Capital (ROIC) | -95.44% |
| Return on Capital Employed (ROCE) | -63.03% |
| Asset Turnover | 0.40x |
| Inventory Turnover | 0.40x |
| Receivables Turnover | 3.68x |
| Cash Conversion Cycle | 806 days |
Scores
PTHS has an Altman Z-Score of -2.14, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -2.14 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $51.29M over the last 12 months.
| Revenue | $51.29M |
|---|---|
| Revenue Growth (YoY) | +592.92% |
| Gross Profit | $42.68M |
| Operating Income | -$52.11M |
| Pretax Income | -$84.97M |
| Net Income | -$78.05M |
| EBIT | -$61.38M |
| Reported EPS (TTM) | -$17.06 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $17.69M |
|---|---|
| Total Debt | $65.25M |
| Net Debt | $47.56M |
| Net Debt Per Share | $12.31 |
| Working Capital | $24.63M |
| Shareholder Equity | -$6.19M |
| Tangible Book Value | -$67.21M |
| Total Assets | $128.82M |
| Total Liabilities | $135.00M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $355.00K of capital spending, operating cash flow left -$32.56M of free cash flow.
| Operating Cash Flow | -$32.21M |
|---|---|
| Capital Expenditures | $355.00K |
| Free Cash Flow | -$32.56M |
| FCF Per Share | -$8.28 |
| Depreciation and Amortization | $6.26M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -101.59%.
| Gross Margin | 83.20% |
|---|---|
| Operating Margin | -101.59% |
| Pretax Margin | -165.66% |
| Net Margin | -152.16% |
| EBIT Margin | -119.66% |
| FCF Margin | -63.48% |
Stock Splits
The last split was a 1-for-10 reverse split on Jul 2, 2025.
| Last Split Date | Jul 2, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Peer Position
Against 3 similar companies, PTHS has the lowest P/S.
P/S RatioPeer median 2.1x
ROICPeer median -170.49%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 0.5x vs 2.1x median |
|---|---|
| ROIC | -95.44% vs -170.49% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +592.92% vs -100.00% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PTHS
What is PTHS's market cap?
Pelthos Therapeutics has a market cap of $28.10M. Its enterprise value, which adds debt and subtracts cash, is $75.67M.
How many shares of PTHS are outstanding?
Pelthos Therapeutics has 3.86M shares outstanding. The count is up 26.17% from a year earlier.
Does PTHS pay a dividend?
No. Pelthos Therapeutics does not pay a dividend.
How much debt does PTHS have?
Pelthos Therapeutics has $65.25M of total debt and $17.69M of cash and equivalents, a net debt position of $47.56M.
PTHS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors